Smart bedside diagnostic platform for oncologic patient profiling and personalized treatment selection
ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. ONCOSMART analyses bone marrow or blood samples from a specific cancer patient, providing the results within 24-48 hours. This “functional profiling” approach has shown superior performance in non-automated systems to current molecular/genomic methods in predicting individual patient’s response to anticancer treatments.
ONCOSMART is a fully-automated and standardised functional profiling platform that is made available to doctors and researchers to identify the most suitable cancer therapy for individual patients and also aid patient selection in clinical trials.
The innovative platform analyses the interactions between anticancer drugs and live tumor cells contained in 2 mL of blood or bone marrow samples.
The platform has been fully-engineered and tested on leukemia patients (AML), proving its predictive power, and is extended to other hematologic and solid tumors in future developments. Within this project, CellPly has the goal to industrialise the platform, validate its analytical and clinical performance and support the first commercialisation activities releasing the platform for research first, then for clinical use.
Project results: Download the final report
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823614
ONCOSMART can test anticancer drugs including targeted, chemo and immunotherapies alone or in combination. The test results guide the selection of:
1) the appropriate therapy for a specific patient
2) cancer patients for specific clinical studies
3) cancer patients for novel therapies in clinical development